The identification of high-risk subtypes (hypodiploidy, ETP-ALL, rearrangements of KMT2A, immature T-cell, Ph positive, TCF-HLF) may respond to a bcl-2 inhibitor, venetoclax [74]. Here, BCL2 is linked to acute lymphoblastic leukemia.